Managing Symptoms For Patients With Myeloproliferative Neoplasms

One expert explained how care team aspects such as open dialogue, support and validation can help to inform patients with MPN about psychosocial needs that tend to be unmet.

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

The FDA approved Ojjaara for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Laura Michaelis, a 2019 CURE MPN Hero, about how far we’ve come in the myeloproliferative neoplasm space.

Nurse practitioner Charina Toste explains why it is important for patients to be empowered to have educated conversation with their care teams.

Reporting MPN side effects to the care team, regardless of how “little” they may seem, can help determine how to adjust treatment to address these symptoms, an expert said.